Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Revenue (2016 - 2025)

CytomX Therapeutics' Revenue history spans 12 years, with the latest figure at $663000.0 for Q4 2025.

  • For Q4 2025, Revenue fell 98.26% year-over-year to $663000.0; the TTM value through Dec 2025 reached $76.2 million, down 44.82%, while the annual FY2025 figure was $76.2 million, 44.82% down from the prior year.
  • Revenue reached $663000.0 in Q4 2025 per CTMX's latest filing, down from $6.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $50.9 million in Q1 2025 to a low of $663000.0 in Q4 2025.
  • Average Revenue over 5 years is $20.3 million, with a median of $19.4 million recorded in 2022.
  • Peak YoY movement for Revenue: surged 159.94% in 2023, then crashed 98.26% in 2025.
  • A 5-year view of Revenue shows it stood at $11.1 million in 2021, then skyrocketed by 80.77% to $20.1 million in 2022, then soared by 32.22% to $26.6 million in 2023, then skyrocketed by 43.17% to $38.1 million in 2024, then plummeted by 98.26% to $663000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Revenue are $663000.0 (Q4 2025), $6.0 million (Q3 2025), and $18.7 million (Q2 2025).